gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SGHTHealthcareSurgical Instruments

Sight Sciences, Inc. Common Stock (SGHT)

$10.05+6.69%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$10.05▲ 97.06% in range
Nov 3, 2025Low $3.45 · High $10.05Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Sight Sciences closed at $10.05 on Nov 4, up 6.69% — matching its 52-week closing high. Volume of 391.3K shares was 1.36× its 20-day average (above normal).

Split-adjusted performance: +17.4% over one month, +133.7% over six months, +97.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $23.39M, up 19.5% from a year earlier, with a net margin of -19.0%.

Short interest was 1.2M shares at the Oct 15 settlement, down 12.4% from the prior report (3.4% of float, 3.5 days to cover).

Market cap$553.6M55.1M shares
Revenue · quarter$23.4M+19.5% YoY
Diluted EPS$-0.08—
P/E · TTM—P/S 6.6×
Net margin-19.0%Gross 91.4%
Dividend yieldNone
52-week range3.45 – 10.050.0% from high
Volume391.3K1.36× 20-day avg
Volatility · 60d46.7%Annualised
Short % of float3.4%3.5 days to cover
Net cash$39.0MCash $79.8M
Next earnings—Not scheduled
Split-adjusted performance
1W +8.8%1M +17.4%3M +41.7%6M +133.7%YTD +26.7%1Y +97.1%3Y +565.6%5Y −60.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum96
Revenue growth77
Net margin43
Value (low P/E)—
Size63

Industry medians: 6-month return −4.4%, revenue growth +8.9%, net margin −8.2%, P/E 29.7×.

Short interest

Details →
Shares short1.2M−12.4% vs prior
Days to cover3.5Settled Oct 15
% of float3.4%
Short vol. 10d39.9%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SGHTSight Sciences$10.05+6.69%+133.7%+19.5%−19.0%—$553.6M
ANGOAngioDynamics$12.58+7.25%+13.8%+6.9%−8.8%—$529.0MCompare
DCTHDelcath Systems$14.94+3.75%+32.7%+20.6%9.2%974.4$518.4MCompare
RCELAvita Medical$16.18+5.54%+266.1%+17.8%−35.3%—$500.4MCompare
CERSCerus$2.48+5.77%−4.4%+6.3%−0.9%—$498.8MCompare
TCMDTactile Systems Technology$27.71+11.82%+9.5%+7.1%7.8%26.4$627.7MCompare
MDXGMiMedx Group$3.23−0.77%−11.9%−45.2%−13.9%—$470.6MCompare
NPCENeuropace$13.71+11.37%−24.3%+17.1%−27.2%—$470.6MCompare
SSIISS Innovations International$2.26−2.92%−44.4%+39.4%−19.1%—$453.5MCompare

News about Sight Sciences

All news →

No recent articles focused on Sight Sciences.

Quick answers

What does Sight Sciences do?
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
What is SGHT's market cap?
$553.63M, based on the Nov 4 close of $10.05.
Does Sight Sciences pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SGHT is sold short?
1.2M shares, 3.4% of float, as of Oct 15, 2026.
What sector is SGHT in?
Healthcare, in the Surgical Instruments industry.

About Sight Sciences

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

HQ: Menlo Park, CA186 employeesListed Jul 15, 2021sightsciences.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology